- Home
- GNSS vs TCRX Comparison
GNSS vs TCRX Comparison
Compare GNSS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- TCRX
- Stock Information
- Founded
- GNSS 1992
- TCRX 2018
- Country
- GNSS United States
- TCRX United States
- Employees
- GNSS N/A
- TCRX N/A
- Industry
- GNSS Consumer Electronics/Appliances
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- TCRX Health Care
- Exchange
- GNSS Nasdaq
- TCRX Nasdaq
- Market Cap
- GNSS 98.9M
- TCRX 86.6M
- IPO Year
- GNSS N/A
- TCRX 2021
- Fundamental
- Price
- GNSS $1.52
- TCRX $1.57
- Analyst Decision
- GNSS Strong Buy
- TCRX Strong Buy
- Analyst Count
- GNSS 3
- TCRX 6
- Target Price
- GNSS $5.33
- TCRX $9.50
- AVG Volume (30 Days)
- GNSS 81.7K
- TCRX 444.5K
- Earning Date
- GNSS 08-05-2025
- TCRX 08-11-2025
- Dividend Yield
- GNSS N/A
- TCRX N/A
- EPS Growth
- GNSS N/A
- TCRX N/A
- EPS
- GNSS N/A
- TCRX N/A
- Revenue
- GNSS $27,780,000.00
- TCRX $4,421,000.00
- Revenue This Year
- GNSS $91.14
- TCRX $159.20
- Revenue Next Year
- GNSS $75.44
- TCRX N/A
- P/E Ratio
- GNSS N/A
- TCRX N/A
- Revenue Growth
- GNSS N/A
- TCRX N/A
- 52 Week Low
- GNSS $1.46
- TCRX $1.02
- 52 Week High
- GNSS $4.04
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- GNSS 37.88
- TCRX 51.86
- Support Level
- GNSS $1.46
- TCRX $1.39
- Resistance Level
- GNSS $1.60
- TCRX $1.73
- Average True Range (ATR)
- GNSS 0.10
- TCRX 0.15
- MACD
- GNSS 0.01
- TCRX -0.01
- Stochastic Oscillator
- GNSS 15.44
- TCRX 37.58
About GNSS Genasys Inc.
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.